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Abstract
Background: The androgen receptor (AR) plays critical roles in both androgen-dependent and
castrate-resistant prostate cancer (PCa). However, little is known about AR target genes that
mediate the receptor's roles in disease progression.
Results: Using Chromatin Immunoprecipitation (ChIP) Display, we discovered 19 novel loci
occupied by the AR in castrate resistant C4-2B PCa cells. Only four of the 19 AR-occupied regions
were within 10-kb 5'-flanking regulatory sequences. Three were located up to 4-kb 3' of the nearest
gene, eight were intragenic and four were in gene deserts. Whereas the AR occupied the same loci
in C4-2B (castrate resistant) and LNCaP (androgen-dependent) PCa cells, differences between the
two cell lines were observed in the response of nearby genes to androgens. Among the genes
strongly stimulated by DHT in C4-2B cells – D-dopachrome tautomerase (DDT), Protein kinase C
delta (PRKCD), Glutathione S- transferase theta 2 (GSTT2), Transient receptor potential cation
channel subfamily V member 3 (TRPV3), and Pyrroline-5-carboxylate reductase 1 (PYCR1) – most
were less strongly or hardly stimulated in LNCaP cells. Another AR target gene, ornithine
aminotransferase (OAT), was AR-stimulated in a ligand-independent manner, since it was
repressed by AR siRNA knockdown, but not stimulated by DHT. We also present evidence for in
vivo AR-mediated regulation of several genes identified by ChIP Display. For example, PRKCD and
PYCR1, which may contribute to PCa cell growth and survival, are expressed in PCa biopsies from
primary tumors before and after ablation and in metastatic lesions in a manner consistent with AR-
mediated stimulation.
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Molecular Cancer 2007, 6:39 http://www.molecular-cancer.com/content/6/1/39Conclusion: AR genomic occupancy is similar between LNCaP and C4-2B cells and is not biased
towards 5' gene flanking sequences. The AR transcriptionally regulates less than half the genes
nearby AR-occupied regions, usually but not always, in a ligand-dependent manner. Most are
stimulated and a few are repressed. In general, response is stronger in C4-2B compared to LNCaP
cells. Some of the genes near AR-occupied regions appear to be regulated by the AR in vivo as
evidenced by their expression levels in prostate cancer tumors of various stages. Several AR target
genes discovered in the present study, for example PRKCD and PYCR1, may open avenues in PCa
research and aid the development of new approaches for disease management.
Background
Prostate Cancer (PCa) is the most commonly diagnosed
non-cutaneous cancer and the second leading cause of
cancer-related mortality in men [1]. Prostate development
and carcinogenesis are highly androgen dependent [2,3].
By regulating cell proliferation, differentiation and apop-
tosis the androgen receptor (AR) plays a pivotal role in
PCa progression, as well as in normal prostate develop-
ment [2-4]. AR-mediated PCa growth is initially hor-
mone-dependent, and men failing surgical and radiation
therapy are therefore subjected to androgen ablation ther-
apy [5]. Androgen ablation in these cases almost always
leads to tumor regression, but this is inevitably followed
by recurrence of PCa due to the development of castrate-
resistant and often metastatic disease.
Although most recurrent PCa tumors are castrate-resist-
ant, AR expression and function are maintained in
advanced disease [6,7] and the growth of ablation-resist-
ant PCa cells remains AR dependent as exemplified by the
following three lines of evidence. Disruption of the AR by
a specific antibody or ribozyme inhibited proliferation in
ablation-resistant PCa cells in the absence of androgens
[8]. Increased AR expression was necessary and sufficient
to convert androgen-sensitive PCa to an ablation-resistant
state [9]. Finally, specific expression in mouse prostate
epithelial cells of an AR transgene containing a gain-of-
function mutation (with increased basal activity and
response to coregulators), resulted in PCa development in
100% of the animals [10] proving that aberrant AR sign-
aling was sufficient to cause PCa and that under certain
conditions the AR acts as an oncogene.
As AR is a transcription factor, its oncogenic functions are
likely mediated through specific target genes. Prostate spe-
cific antigen (PSA), the best studied AR target gene, is
thought to contribute to PCa progression through its pro-
tease activity [11] and its ability to induce epithelial-mes-
enchymal transition and cell migration [12]. Other AR
target genes implicated in PCa progression are FGF8 [13],
Cdk1 and Cdk2 [14], as well as PMEPA1 [15] and
TMPRSS2 [16]. Interestingly, the AR response mechanism
of TMPRSS2 drives oncogenic Ets family members in
many castrate resistant tumors due to TMPRSS2:Ets chro-
mosomal translocations [17,18]. However, additional, yet
unidentified target genes most likely contribute to the
tumorigenic activity of the AR in PCa. The present study
was undertaken to identify such genes based on their
physical interaction with the AR. C4-2B human PCa cells,
a model for castrate-resistant disease, were subjected to a
procedure called Chromatin Immunoprecipitation
(ChIP) Display (CD) [19] and 19 novel regions occupied
by the AR were discovered. The expression patterns of
genes within the AR-occupied loci, along with functions
attributed to these genes, render some of them potential
PCa therapeutic targets.
Results
ChIP Display of AR targets in C4-2B cells: an example
To identify AR targets in PCa, we employed ChIP Display,
a newly developed method for the identification of
regions occupied by transcription factors in living cells
[19]. C4-2B human PCa cells were stimulated by andro-
gens for 4 hours and ChIP was performed with either AR
or IgG control antibodies. The purified DNA was digested
with AvaII in order to standardize all DNA fragments rep-
resenting each AR-occupied region to one size. The AvaII
fragments were amplified using ligation-mediated PCR
with each of 36 possible nested primer combinations
[19]. The use of nested primers reduces ChIP noise
because all the fragments representing a given locus are
amplified with the corresponding primer combination,
while non-specifically precipitated fragments are scat-
tered, i.e. amplified with other primer combinations [19].
The PCR products are subsequently resolved by polyacry-
lamide gel electrophoresis (PAGE). Figure 1 describes an
example of the procedure leading to the identification of
one novel target, and Table 1 summarizes all the AR tar-
gets identified in this study.
The example shown in Figure 1A entails the amplification
and PAGE of two independent AR-ChIPs and two mock
ChIPs using one of the 36 primer combinations – the 'AC'
and the 'TG' primer (see Methods and Additional file 1).
The arrowheads in Figure 1A point to bands more promi-
nently amplified in the AR ChIPs as compared to the IgG
ChIPs. These bands, representing a putative AR binding
region, were excised, reamplified and further character-Page 2 of 15
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Table 1: AR targets identified in this study
CD Primers1 Band 2 AvaII – AvaII 3 Nearby Genes 4 Position of CD Hit Relative to gene ChIP validation5
C4-2B LNCaP
AT, TA 1p35.2 30,152,547 – 30,152,728 Nearest gene is 626-kb away 4 2
AA, TC 1q25.2 178,433,288 – 178,433,456 QSCN6 [63, 67] exon 13 3 1
LHX4 [68] 32.7-kb 5'
CEP350 84.2-kb3'
ACBD6 90.6-kb 3'
AT, AT 2q37.3 241,348,804 – 241,348,990 KIF1A intron 23/exon 24 3 1
AQP12 62.4-kb 3'
TT, TT 3p21.1 53,169,093 – 53,169,401 PRKCD [51, 53] 0.8-kb 5' 4 nd
AT, AC 4p16.1 6,644,411 – 6,644,619 MAN2B2 intron 5 3 3
MRFAP1 48.7-kb 5'
AA, TC 7q11.23 72,483,118 – 72,483,317 FZD9 [69] 2.7-kb 5' 4 nd
BAZ1B 10k-b 3'
AT, AG 7q11.23 72,922,165 – 72,922,474 WBSCR28 4-kb 3' 4 2
WBSCR27 27.4-kb 5'
CLDN4 [70] 37.2-kb 3'
AA, AG 8q24.3 143,094,298 – 143,094,518 Nearest gene is 197kb away [64] 3 2
AC, TC 10p12.1 24,584,349 – 24,584,579 KIAA1217 intron 2 4 3
AT, AG 10q26.13 126,072,189 – 126,072,473 OAT 3.4-kb 3' 2 0
LHPP 67.9-kb 5'
AC, TC 11p15.4 1,017,234 – 1,017,529 MUC6 [58] 10-kb 5' 3 3
AP2A2 15-kb 3'
AT, AT 11q12.3 62,532,814 – 62,532,977 SLC22A8 intron 2 5 2
SLC22A6 23.9-kb 5'
CHRM1 87.3-kb 5'
AT, AT 11q25 134,102,859 – 134,103,167 Nearest gene is 315-kb away 2 3
AT, AT 14q31.3 86,510,091 – 86,510,360 Nearest gene is 959-kb away 3 2
AT, AC 17p13.2 3,446,846 – 3,447,080 TRPV1 exon 1/intron 1 3 1
CARKL 11.4-kb 3'
TRPV3 [60, 61] 39-kb 5'
AC, TG 17q25.3 77,480,155 – 77,480,527 MAFG 1.5-kb 5' 4 2
PYCR1 [36, 50] 2.5-kb 3'
SIRT7 [71, 72] 12-kb 5'
AA, AA 22q11.23 22,655,127 – 22,655,462 GSTT2 [62] exon 4/intron 4 3 2
DDT 3.1-kb 5'
AG, AG 22q13.1 38,101,611 – 38,101,989 SYNGR1 intron 2 3 2
MAP3K7IP1 25-kb 5'
AC, TC 22q13.3 48,707,684 – 48,707,956 CRELD2 1-kb 3' 3 1
ALG12 10-kb 5'
1CD primers are defined based on two variable nucleotides as described in Methods.
2Cytogenetic band containing the CD hit.
3Absolute positions of the AvaII sites flanking the fragment displayed by PAGE.
4The nearest Refseq gene annotated in Ensembl [65] is shown in bolded and italicized text. Published papers suggesting relevance to cancer are referenced near the 
respective gene name.
5Number of independent conventional ChIP assays in which AR occupancy was confirmed. nd, not determined.
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trophoresis (Figure 1B). The major HaeIII digestion
product from each of the two ChIPs was sequenced and
mapped to human chromosome 17q25.3, 1.5-kb
upstream of the MAFG gene and 2.5-kb 3' of the PYCR1
gene (Figure 1C). The AvaII fragment displayed in the
original PAGE (Figure 1A), depicted in Figure 1C as "hit",
does not contain repetitive sequences and is located
between two canonical Androgen Receptor Elements
(AREs) (Figure 1C). A 2.4-kb CpG island is present adja-
cent to the hit (Figure 1C).
To validate AR occupancy at the region described above,
we performed conventional ChIP assays with locus-spe-
cific primers (see Additional file 1). Four independent
experiments with C4-2B cells showed that the PYCR1/
MAFG locus was enriched in AR ChIPs as compared to
paired IgG control ChIPs (Table 1, and see a representa-
tive result in Figure 1D).
ChIP Display discloses 19 novel AR binding sites in PCa 
cells
The CD procedure, exemplified above for the 'AC' and
'TG' primer pair, was performed using all 36 possible
primer combinations [19], resulting in the identification
of 19 novel AR-occupied regions in C4-2B cells (Table 1).
AR occupancy at the novel AR binding regions was con-
firmed in independent conventional ChIP assays of C4-2B
cells (Table 1). Whereas only four of the 19 AR binding
regions were up to 10-kb 5' of the nearest gene (indicated
by bolded and italicized text in Table 1), many of the
binding regions were either within the body of annotated
genes (8 of the 19 regions) or up to 4-kb 3' of the nearest
gene (3 of the 19 regions), indicating that AR-bound
regions are not preferentially found within so-called 5'-
flanking gene regulatory sequences. Four of the 19 CD hits
were mapped to regions more than 197-kb away from any
annotated gene (Table 1).
An important enigma in prostate cancer research is the
molecular nature of the transition from androgen-
dependent to castrate-resistant disease. In this context, the
C4-2B cell line serves as a model of the latter, whereas its
parent cell line, LNCaP, serves as a model of the former
[20]. We speculated that many of the AR-occupied regions
in C4-2B cells could become targets for this transcription
factor only during the transition from androgen depend-
ence to castrate-resistance and would therefore not be
occupied by the AR in LNCaP cells. However, results of
ChIP analysis in LNCaP cells were inconsistent with this
notion, as 16 of 17 regions that we tested, which were
occupied by the AR in C4-2B cells, were also occupied in
LNCaP cells at least in one conventional ChIP assay
(Table 1). Be that as it may, several of the AR-occupied
regions are located near genes that have been linked to
prostate or other cancers (see Discussion below and refer-
ences in Table 1).
AR occupied regions are associated with DHT-stimulated 
and DHT-repressed genes in C4-2B cells
One of the goals of this study was to identify primary AR-
responsive target genes in PCa cells. Of the 19 AR-occu-
pied regions, 15 were within 10-kb of Refseq-annotated
ChIP Display (CD) demonstrates a putative AR targetFigure 1
ChIP Display (CD) demonstrates a putative AR tar-
get. A) CD Gel. C4-2B cells were treated with 10 nM DHT 
for 4 hours to enhance AR association with target loci. Two 
independent AR ChIPs, and IgG control ChIPs were sub-
jected to the CD procedure as described in Methods. In the 
example shown here, PCRs were performed with the 'AC' 
and the 'TG' PCR primers (see Methods and Additional file 1) 
with the annealing temperature set at either 70°C or 71°C as 
indicated. Amplified products were resolved using 8% PAGE 
and visualized by EtBr staining. The arrowheads point at 
bands amplified more prominently in the AR compared to 
the Control (IgG) lanes. M, marker DNA; numbers above 
bands indicate size in bps. B) Re-amplification and diges-
tion. The two bands indicated in panel A by arrowheads 
were excised, purified and re-amplified with the same 'AC' 
and 'TG' primers used for CD. The products were subjected 
to secondary digestion with the indicated enzymes, followed 
by agarose gel electrophoresis. Arrowheads point at similar 
HaeIII sub-fragments obtained from the two AR ChIPs. – C, 
no template control, UC, uncut, M, marker DNA. C) Map-
ping of AR target. The HaeIII subfragments from B were 
excised, purified and sequenced. By blasting against the 
human genome using Ensembl [65], both sequences mapped 
to chromosome 17q25.3, ~1.5-kb upstream of the MAFG 
gene and ~2.5-kb downstream of the PYCR1 gene as shown 
in the diagram. The two genes are transcribed in the same 
direction as indicated by the horizontal arrows. pA, polyade-
nylation signal. The AR binding region discovered through 
CD (''hit'') abuts a CpG island (bottom, striped rectangle), but 
does not overlap with any repetitive elements (bottom, black 
rectangles). Several AREs (checkerboard triangles) were identi-
fied in this region using Consite [66]. D) Validation of tar-
get by conventional ChIP analysis. AR occupancy at the 
PYCR1/MAFG locus was tested by conventional ChIP assay. 
The PSA enhancer serves as positive control. A non-target 
locus serves as the negative control. Genomic DNA was 
used to demonstrate that the ChIP amplification was per-
formed within a dynamic range. – C, no template control. M, 
marker DNA.Page 4 of 15
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Molecular Cancer 2007, 6:39 http://www.molecular-cancer.com/content/6/1/39genes. We initially measured the androgen responsiveness
of genes nearest to each of these 15 AR-occupied regions
(gene names bolded and italicized in Table 1). C4-2B cells
were depleted from steroids, and treated with DHT or
vehicle for 0, 2, 4, 8, 16, 24 or 48 hours. Gene expression
was assessed by RT-qPCR. Of the 15 genes nearest AR
occupied regions, expression of all but SLC22A8 was
detectable, and only 6 of the remaining 14 genes
responded to DHT treatment in a consistent manner.
CRELD2, PRKCD and GSTT2 were stimulated (Figure 2B,
C, D, solid lines), whereas MUC6, KIAA1217, and
WBSCR28 were repressed (Figure 2ZC, ZE, ZF, solid
lines). Because the remaining 8 of 15 genes nearest the AR
occupied regions did not respond to DHT, we tested the
expression of 19 additional nearby genes, up to 100-kb
away from AR occupied regions. Of these 19 genes, the
expression of all but AQP12 was detectable, but only eight
responded to DHT treatment. DDT, TRPV3, PYCR1,
AP2A2, ACBD6, SIRT7 and MRFAP1 were stimulated (Fig-
ure 2A and 2E–J, solid lines), and CHRM1 was repressed
(Figure 2ZD). Altogether, of 32 genes within 100-kb from
AR-occupied regions, many of which have been impli-
cated in cancer progression (see references next to gene
names in Table 1), ten were stimulated and four were
repressed in DHT-treated C4-2B cells. More detailed
investigation of the repressed genes is described elsewhere
[21]. Notably, there were four loci in bands 2q37.3,
7q11.23, 10q26.13 and 22q13.1, where no nearby genes
responded to DHT despite AR occupancy (Table 1 and Fig-
ure 2).
AR-dependent, DHT-independent regulation of OAT and 
MRFAP1
Genes near AR-occupied regions that did not respond to
DHT could still be regulated by the AR in a ligand-inde-
pendent manner. To address this possibility, we treated
C4-2B cells with AR siRNA duplexes [22] and assessed the
effects on gene expression in the absence (and presence –
as control) of DHT. Of eight genes near the four AR-occu-
pied regions that were not associated with DHT-respon-
siveness in C4-2B cells, we found one, OAT, which was
repressed in three of three siRNA experiments (Figure 3A),
suggesting that it is indeed stimulated by the AR in the
absence of ligand, despite its DHT non-responsiveness
(Figure 2L). The other seven genes, KIF1A, AQP12, FZD9,
BAZ1B, LHPP, SYNGR1 and MAP3K7IP1 did not respond
to the siRNA treatment (data not shown), suggesting that
AR occupancy at these loci may be without functional
consequences in cultured C4-2B cells.
As controls for the AR siRNA experiments we also meas-
ured expression of AR itself and the DHT-stimulated genes
PSA [23], PRKCD, PYCR1 and MRFAP1 (Figure 2C, F, J).
As expected, the AR knockdown (Figure 3B) was associ-
ated with loss of DHT-stimulation (Figure 3C, D, and 3E).
Interestingly, however, one of these controls, MRFAP1,
displayed an unexpected phenotype. In addition to the
DHT-stimulation, it was reproducibly stimulated in cells
treated with AR siRNA (Figure 3F). Taken together, our
data suggest that unliganded AR supports basal OAT
expression (Figure 3A) without further stimulation by
DHT (Figure 2L), while basal MRFAP1 expression is sup-
pressed by unliganded AR (Figure 3F), yet stimulated by
DHT (Figure 2J).
Differential regulation of genes near AR-occupied regions 
in LNCaP versus C4-2B cells
Although most of the regions occupied by the AR in C4-
2B cells (a model of castrate-resistant PCa) were also occu-
pied in LNCaP cells (a model of androgen-dependent
PCa) (Table 1), we suspected that the functional conse-
quences of AR occupancy at these loci might differ
between the two cell lines. We therefore complemented
the DHT time course studies in C4-2B cells (Figure 2, solid
lines) with parallel expression analysis of the same genes
in LNCaP cells under a similar experimental protocol (Fig-
ure 2, dashed lines). Both similarities and differences
between the two cell lines were observed. The three genes
most strongly stimulated by DHT in C4-2B cells – DDT,
CRELD2 and PRKCD – were also stimulated in LNCaP
cells (Figure 2A, B, C), although the stimulation of DDT
and PRKCD was more modest in LNCaP cells. Genes that
were more moderately stimulated by DHT in C4-2B cells
were slightly (PYCR1, Figure 2F) or not at all stimulated in
LNCaP cells (GSTT2, AP2A2, ACBD6, and SIRT7; Figure 2,
panels D, G, H, I). Repressed genes displayed a mirror
image. The four genes most strongly repressed in C4-2B
cells – MUC6, CHRM1, KIAA1217, and WBSCR28 – were
also repressed in LNCaP cells, but repression generally
occurred faster in the C4-2B cells (Figure 2ZC, ZD, ZE,
ZF). Subtle responses to DHT were less consistent between
C4-2B and LNCaP cells, although three genes, CARKL,
MAN2B2, and LHX4, displayed remarkably similar
expression patterns (Figure 2, panels M, N, O).
An emerging concept in PCa research is that ligand-inde-
pendent AR-mediated gene expression contributes to the
acquisition of a castrate-resistant growth state. If the deri-
vation of C4-2B from LNCaP cells [20] were associated
with such a mechanism, then one could expect expression
of some genes near AR-occupied regions to be higher in
hormone-deprived C4-2B as compared to hormone-
deprived LNCaP cells. We therefore compared expression
of the 32 genes near the AR-occupied regions between the
two cell lines, and found four that were expressed in C4-
2B cells at levels between 2 and 12-fold higher than in
LNCaP cells (Figure 4). Not surprisingly, one of these
genes was OAT, which was repressed after AR knockdown
in C4-2B cells (Figure 3A). The other three were QSCN6,
GSTT2, and TRPV3. Interestingly, two genes, KIF1A andPage 5 of 15
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Gene expression analysisFigur  2
Gene expression analysis. C4-2B (solid lines) and LNCaP cells (broken lines) were maintained in 5% CSS-containing 
medium for three days, and then re-fed (time 0) with the same medium supplemented with either 10 nM DHT or ethanol vehi-
cle. RNA was extracted at the indicated time points during the time course and expression of the specified genes was meas-
ured by RT-qPCR. Expression levels relative to 18S rRNA (which itself stayed stable throughout the time course) are shown 
with the 0 time values defined as 1 for each cell line. Representative data is shown from one of two independent experiments 
with n = 3, except for panels 2L, O, U, Y and ZC, where the C4-2B data is derived from 6 measurements (see Additional file 3 
for the complete set of raw data). Error bars are SEM. Genes are roughly ordered based on the DHT-responsiveness in C4-2B 
cells, with stimulated genes first (panels A-J) to repressed genes last (panels ZC-ZF). TRVP3 mRNA was barely detectable in 
LNCaP cells.
Molecular Cancer 2007, 6:39 http://www.molecular-cancer.com/content/6/1/39MAN2B2, were 2 fold less expressed in C4-2B than in
LNCaP cells. Thus, differences in gene expression between
LNCaP and C4-2B cells, both under androgen deprivation
and after DHT stimulation, may be involved in mecha-
nisms of progression from early to late stage disease.
Clinical relevance of novel AR target genes
To examine whether genes found in proximity to AR-occu-
pied regions in our culture model are potentially regu-
lated by the AR during PCa progression, we mined our
microarray database of gene expression profiles in PCa
tumors [24]. Figure 5 illustrates expression of the in vitro
CD-disclosed genes in 23 untreated primary PCa tumors,
17 primary tumors after 3 months of androgen ablation
therapy and 7 AR-positive metastatic tumors. Expression
of several of these genes was consistent with in vivo regu-
lation by the AR. As shown in Figure 5, Group II, the
mRNAs for PYCR1, DDT, PRKCD, and CRELD2, which
were DHT-stimulated in vitro (Figure 2), were decreased in
the androgen-ablated as compared to the primary
untreated tumors. Furthermore, when compared to the
androgen-ablated tumors, the expression of these four
genes was elevated in the metastatic tumors (Figure 5),
presumably due to reactivation of the AR [5,25]. The sim-
ilarity between the expression profiles of the CD-disclosed
targets PYCR1, DDT, PRKCD, and CRELD2 in the clinical
samples and those of the established AR target genes PSA/
KLK3 [11] and TMPRSS2 [16] (Figure 5, Group I) suggests
that the four genes discovered in our in vitro study are
indeed AR targets in vivo. Interestingly, expression of
ALG12 and CHRM1, which were unresponsive or even
repressed by DHT in vitro, were decreased in androgen-
ablated as compared to untreated primary tumors (Figure
5, group II), suggesting positive regulation by the AR in
vivo, possibly via mechanisms not operative in our cell
culture system. Five probesets displayed a profile indica-
tive of AR-mediated repression in vivo (Figure 5, Group
III). Of the corresponding five genes, KIAA1217 was
strongly inhibited, while QSCN6 and SYNGR1 were only
slightly inhibited by DHT in vitro (Figure 2Z and 2ZB).
Notably, the evidence for KIAA1217 repression in vivo was
provided by only one probeset (located at the 3'UTR,
close to the region targeted by our RT-qPCR primers) and
not by five other KIAA1217 probesets present on the array
(Figure 5, Group IV). The remaining two genes in Group
III (Figure 5), MRFAP1 and OAT, appear to be negatively
regulated by the AR in vivo, although they were stimulated
or non-responsive to DHT in vitro (Figures 2J and 2L).
Interestingly, both these genes were regulated by unlig-
anded AR in vitro (Figure 3). Thus, the expression profiles
in the PCa biopsies suggest AR-mediated regulation of
CD-disclosed AR target genes in vivo, although the nature
of the in vivo response is not always consistent with that
seen in vitro.
Gene expression in C4-2B versus LNCaP cellsFigur  4
Gene expression in C4-2B versus LNCaP cells. RNA 
was extracted from C4-2B and LNCaP cultures that were 
maintained for two days in CSS-supplemented medium. Gene 
expression was analyzed side-by-side by RT-qPCR and cor-
rected for 18S rRNA. Bars represent the comparative ratio 
between the expression in C4-2B and LNCaP cells, where 
the expression level in LNCaP cells is defined as 1. Included 
in this Figure are only genes for which the expression levels 
were significantly different between the two cell lines in two 
independent experiments (n = 3; Mean ± SD). TRPV3 mRNA 
was detected in LNCaP cells in only one of the three meas-
urements, and this value was used as the upper limit for 
TRPV3 expression in these cells. See additional file 4 for 
details.
Effects of AR siRNA-knockdown on gene expressionFigure 3
Effects of AR siRNA-knockdown on gene expression. 
C4-2B cells were treated with AR siRNA (white bars) or a 
non-specific siRNA (black bars), followed by administration 
of either DHT (10 nM) or Ethanol vehicle for 16 hours. 
Expression levels of the indicated genes were analyzed in 
triplicate by RT-qPCR and corrected for 18S rRNA levels. 
Values measured with the non-specific siRNA and ethanol 
were defined as 1. Results (Mean ± SD) are representative of 
three independent experiments.Page 7 of 15
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Expression of CD-disclosed genes in PCa tumorsFigure 5
Expression of CD-disclosed genes in PCa tumors. RNA from 47 PCa tumors (columns) was analyzed using Affymetrix 
U95 A-E microarray sets (21) and results are mined for all probesets (rows) interrogating each of the 32 CD-disclosed genes 
(Table 1). Heat map shows relative expression for each of the indicated probesets, where darker shades represent higher 
mRNA levels. Tumors included 23 primary prostate cancers from patients not receiving therapy (primary), 17 primary prostate 
cancers following 3-month neoadjuvant androgen ablation therapy (primary+AAT), and 7 AR-positive metastatic lesions (mets). 
All Grade A probesets interrogating each gene are shown, except for probesets 59776_at (WBSCR28) and 36904_at (KIF1A), 
which did not detect significant expression in any sample. Samples are grouped and ranked as follows. Group I – probesets for 
the known AR-stimulated genes KLK3/PSA and TMPRSS2. Group II – probesets exhibiting statistically greater mean expression 
in untreated compared to AAT-treated primary PCa samples (p < 0.05), thereby representing putative AR-stimulated genes. 
Group III – probesets exhibiting statistically lower mean expression in untreated compared to AAT-treated PCa samples (p < 
0.05), thereby representing putative AR-repressed genes. Group IV – probesets exhibiting no statistical difference between sam-
ples without or with AAT. Probesets in Groups II-IV are ranked by p-value in descending order.
Molecular Cancer 2007, 6:39 http://www.molecular-cancer.com/content/6/1/39Discussion
AR occupancy is not biased towards 5' promoter-proximal 
regions
The classical view of gene regulation places 5'-flanking
sequences at the center stage. Consistent with this view,
functional AREs have been mapped within 0.5-kb
upstream of the AR-responsive genes probasin, KLK2 and
KLK3 (PSA) [26-28]. While four of the 19 AR-occupied
regions disclosed in our study were located within 10-kb
upstream of annotated transcription start sites, many
more were found within gene bodies (8/19) or within the
4-kb sequences downstream from the 3' ends of anno-
tated genes. Our findings are consistent with several
recent genome-wide location analyses of other transcrip-
tion factors. For example, only 4% of estrogen receptor
(ER) binding sites were mapped to 1-kb promoter-proxi-
mal regions by ChIP-chip analysis [29]. Similarly,
genome-wide location analysis indicates that p53 has no
preference for binding to 5' promoter-proximal regions
[30]. Thus, accumulating evidence suggest that promoter-
proximal regions constitute only a small fraction of mam-
malian gene regulatory sequences.
Many of the AR-occupied regions identified in the present
study, which cannot be designated classical 5' promoter
regions, were still close to annotated genes that they could
potentially regulate. There is no consensus as to how far a
transcription factor-binding region should be in order to
be considered a putative cis-acting regulatory domain for
a given gene. Values 1-kb, and up to 100-kb from the tran-
scription start site have been used by various investigators
[29,30], but experimental evidence in support of any
value is scarce. Systematic analyses of transcription factor
binding regions across the genome have become feasible
only recently. Such studies, including the present one,
illustrate the need for mutagenesis of transcription factors
binding regions that are distant from annotated genes in
order to identify functionally relevant regions. In particu-
lar, it would be interesting to decipher the role of binding
regions located hundreds of kbs away from the nearest
annotated gene. Such regions may still regulate distant
annotated genes on the same [31] or even other chromo-
somes [32], or they may regulate nearby unannotated
transcripts [33].
AR location analysis discloses ligand-independent, AR-
dependent gene regulation
Comprehensive gene expression analysis is frequently
employed for the discovery of target genes for transcrip-
tion factors, including the AR [24,34-36]. Such expression
analyses cannot differentiate between direct and indirect
targets and they do not provide information on the loca-
tion of regulatory elements. Another, frequently under-
appreciated limitation of expression studies is that they
only disclose target genes that respond to the transcription
factor of interest under the specific experimental condi-
tions utilized by the investigator. In contrast, ChIP Dis-
play and other approaches for location analysis (see
below) rely on physical interaction, not gene expression.
These approaches allow the discovery of target genes that
expression studies would potentially miss. For example,
in the present study, we discovered OAT as an AR-regu-
lated gene, although it did not respond to DHT. AR-target
genes could also be missed in expression-based studies
because of the limited sensitivity and specificity of micro-
array hybridization as compared to RT-qPCR. Experimen-
tal approaches for location analysis are constantly
improving and include many that are far more compre-
hensive than ChIP Display, for example ChIP-chip [37-
39], SABE [40], STAGE [41], ChIP-PET [30], GMAT [42],
SACO [43] and DamID [44]. However, the present study
demonstrates that important information can be obtained
with ChIP Display, a relatively inexpensive sampling
method that can be performed in any molecular biology
laboratory. Of course, each of the expression and the loca-
tion approaches for target identification should ideally be
complemented appropriately. In the present study, we
showed that many (but not all) of the genes near AR-occu-
pied regions are DHT-responsive. For OAT, which was dis-
closed here by ChIP Display and could not have been
disclosed by comprehensive analysis of gene expression in
response to androgen treatment, we used siRNA knock-
down to demonstrate the ligand-independent regulation
by the AR. Furthermore, of the genes near AR-occupied
regions that responded to neither DHT nor AR siRNA in
our study, some may be AR-regulated under specific, pos-
sibly transient physiological or pathological conditions
not modeled by the experimental systems we employed.
This is particularly important in the context of castrate-
resistant PCa, where AR activation can occur through var-
ious signaling pathways, including Her2, AKT, and MAPK
[25].
Differential basal gene expression in C4-2B versus LNCaP 
cells
The AR plays critical roles during all stages of PCa progres-
sion [5,9,45]. It is not clear, however, whether AR regu-
lates different sets of genes before and after ablation
therapy. In our study, AR occupancy at most of the regions
disclosed by CD was similar in LNCaP and C4-2B cells,
models of early and late stage PCa, respectively. Our data
is therefore consistent with the idea that the AR continues
to regulate the same genes before and after ablation ther-
apy, but that the nature of this regulation alters during dis-
ease progression. For many genes near AR-occupied
regions, ligand-bound AR had the same qualitative effects
in the two cell lines, except they were stronger in the C4-
2B as compared to the LNCaP model (e.g., DDT, PRKCD,
GSTT2, PYCR1; Figure 2). Some other genes near AR-occu-
pied regions were found to express at higher basal levelsPage 9 of 15
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TRPV3; Figure 4). The higher basal expression of these
genes could be a direct result of ligand-independent acti-
vation by the AR due to, for example, cofactor expression
[46,47] and/or chromatin reorganization [22]. Accumula-
tion of mutations during the derivation of C4-2B from
LNCaP cells could also contribute to differential basal and
DHT-responsive expression, although the two cell lines
are mostly isogenic as indicated by our microsatellite
analysis (see Additional file 2).
Evidence from PCa biopsies for in vivo AR-mediated 
regulation of genes disclosed by ChIP Display
In the present study, we included analysis of the ChIP Dis-
play-disclosed genes for their expression in PCa biopsies.
This analysis provided evidence that AR regulates in vivo
several of the ChIP Display-disclosed genes. This notion,
however, remains tentative because the clinical material
used for the microarray expression analysis is no longer
available for confirmation by RT-PCR. To increase our
confidence in the microarray data, we only considered
results from probesets that are considered highly reliable
(Affymetrix' grade A annotation). Results from the PCa
biopsies were consistent with those from the in vitro gene
expression analysis for the positively regulated genes
PYCR1, DDT, PRKCD, and CRELD2. However, ALG12
and TRPV1, which appear to be stimulated by the AR in
vivo, were not responsive to either DHT or AR siRNA in
vitro. The in vivo and in vitro analyses were less well corre-
lated for negatively regulated genes. Only one of six
probesets interrogating KIAA1217 expression indicated
repression in vivo, although this gene was strongly inhib-
ited in vitro. CHRM1 was also strongly repressed by andro-
gens in vitro, yet it was found to be stimulated in vivo. OAT,
which appears to be downregulated by the AR in vivo, was
stimulated in vitro in a ligand independent manner. It
remains to be seen whether these inconsistencies result
from differential requirements for AR-mediated gene
stimulation/repression in vitro and in vivo, the presence of
multiple splicing isoforms, or simply erroneous microar-
ray expression scores. Be that as it may, further investiga-
tion of genes highlighted by our study, and especially
genes for which results from the PCa biopsies are appar-
ently inconsistent with the in vitro results, will have to start
with validation of the regulation of such genes in PCa in
vivo.
Novel AR target genes: potential mechanisms contributing 
to PCa progression
PSA (KLK3) remains the most well studied AR target gene
in the PCa literature to date. Since its approval in 1986,
serum PSA is routinely used to aid the early diagnosis and
prognosis of PCa in men. However, AR-driven PSA expres-
sion alone does not fully explain the role of AR in PCa
development and progression. Although additional AR
target genes have been recently discovered, e.g., FKBP5
[48] and TMPRSS2 [16], most remain elusive. Some of the
AR target genes discovered in the present study, and more
to be discovered in the future, may open new research ave-
nues and help develop novel therapeutic approaches to
manage PCa.
PYCR1
Pyrroline-5-carboxylate reductase 1 (PYCR1) catalyzes the
NAD(P)H-dependent conversion of pyrroline-5-carboxy-
late (P5C) to proline. Stimulation of PYCR1 by the AR
could contribute to PCa progression because P5C is pro-
apoptotic [49] and proline is anti-apoptotic [50]. Indeed,
a role for PYCR1 in PCa was suggested by a 4-fold
increased expression in human prostate tumors compared
to adjacent normal tissue [36]. In the present study we
demonstrate AR occupancy at the PYCR1 locus in living
PCa cells, the functionality of which is suggested by DHT-
mediated stimulation of gene expression. Consistent with
these in vitro data, we also demonstrate decreased PYCR1
expression in PCa biopsies from men undergoing andro-
gen ablation therapy as compared to untreated controls.
The highest PYCR1 expression in our PCa samples was
found in biopsies from metastatic tumors, possibly as a
result of atypical AR activation. Of the AR targets discov-
ered in the present study, PYCR1 is a strong candidate for
mediating the oncogenic action of AR signaling in PCa.
OAT
Interestingly, another AR target gene discovered in this
study also participates in proline metabolism. Ornithine
aminotransferase (OAT) converts ornithine to glutamate
γ-semialdehyde, which spontaneously cyclizes to form
pyrroline-5-carboxylate (P5C), a proline precursor and
the substrate for PYCR1. The functional evidence for AR-
mediated regulation of OAT is weaker than that for
PYCR1. While OAT mRNA was not significantly altered in
response to DHT, it was repressed after siRNA-mediated
knockdown of the AR, and also displayed a 3.3-fold
higher basal expression in C4-2B as compared to LNCaP
cells. Interestingly, OAT's expression pattern in our tumor
samples does not suggest AR-mediated stimulation, but
rather repression, possibly reflecting interactions of AR
signaling with input from other cell types or components
of the extracellular matrix, which only occur in vivo.
PRKCD
In this study, we mapped AR occupancy to a region 0.8-kb
upstream of the gene encoding Protein Kinase C delta
(PRKCD), which has received much attention in the PCa
literature. PRKCD mRNA levels were higher in DHT-
treated as compared to untreated PCa cell cultures and
were reduced in PCa biopsies from patients undergoing
androgen ablation therapy as compared to those from
untreated patients. The observed high PRKCD mRNA lev-Page 10 of 15
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ent AR activation, possibly play a role in late stage disease
because PRKCD is implicated in growth, migration and
invasion of cancer cells, including PCa [51,52]. PRKCD
has also been implicated in the control of cell survival,
although most studies suggest it is in fact pro-apoptotic
[53-55]. Future studies will have to address how PRKCD's
pro-apoptotic activity is overcome in advanced PCa cells.
CRELD2 and DDT
The gene expression data form both the cell culture mod-
els and the clinical tumor samples suggest androgen-
mediated stimulation of CRELD2 and DDT. Although a
role for CRELD2 in carcinogenesis remains to be investi-
gated, this Cysteine-rich with EGF-like Domains 2
(CRELD2) protein has been shown to interact with neuro-
nal acetylcholine receptors [56]. Likewise, no role in
tumor progression has been assigned yet to DDT, a pro-
tein with homology to macrophage migration inhibitory
factor (MIF) [57].
MUC6
Among the few genes near AR-occupied regions that were
repressed by DHT was MUC6. Mucin 6 is a secreted glyc-
oprotein that forms a protective gel layer around the pro-
ducing cell [58]. Other mucins are aberrantly expressed in
cancer [58] and MUC2 was ascribed a tumor suppression
function [59]. Conceivably, AR-mediated MUC6 repres-
sion can contribute to PCa progression. Notably, how-
ever, MUC6 mRNA was neither increased in the
androgen-ablated compared to the untreated tumors, nor
was it absent in the metastatic samples. Although our in
vivo data does not support a role for MUC6 in PCa pro-
gression, MUC6 could still play a transient role during a
short period of time not captured by our clinical samples.
TRPV3 and GSTT2
Like the androgen-repressed MUC6, evidence for roles for
the androgen-stimulated TRPV3 and GSTT2 genes in PCa
progression is suggested only from our in vitro data. These
two genes are not only androgen stimulated but are also
expressed in C4-2B cells more strongly than in LNCaP
cells. TRPV3 is a member of the transient receptor poten-
tial (TRP) family of thermosensory ion channel genes.
Another member of this family, TRPV6, potentiates cal-
cium-dependent cell proliferation [60], and its expression
has been linked to human PCa progression [61]. Glutath-
ione S-transferase theta 2 (GSTT2) belongs to a family of
detoxification enzymes, overexpression of which is
thought to provide cells with protection against oxidative
stress and various drugs [62].
AR occupancy at PCa-linked loci
Two of the AR-occupied regions disclosed by ChIP Dis-
play were near loci previously linked to PCa: (i) the hered-
itary prostate cancer 1 (HPC1) locus, which has been
mapped to 1q24-25 [63]; and (ii) the 8q24 locus, recently
linked to PCa through admixture mapping in African
American men [64]. Although fine mapping of specific
genetic elements has not been achieved yet for either of
these loci, their contribution to PCa progression in a
mechanistic sense may be related to the observed AR occu-
pancy.
Conclusion
We have identified 19 novel AR-occupied regions in PCa
cells, many of which are associated with genes that are reg-
ulated by the AR in either a ligand-dependent or ligand-
independent manner. Furthermore, some of the newly
identified AR target genes are differentially regulated in
cell models for, and/or biopsies from, different stages of
PCa progression. These genes provide opportunities for
future research to better understand the role of the AR in
PCa and eventually improve patient care, especially in the
context of castrate-resistant disease.
Methods
Cell culture and materials
Human C4-2B cells, a model for castrate-resistant PCa,
were obtained from ViroMed Laboratories Inc. (Minne-
tonka, MN) and their parental, androgen-dependent
LNCaP cells, were obtained from ATCC. (Manassas, VA).
The close relationship between the two cell lines was con-
firmed by microsatellite analysis at ten loci (see Addi-
tional file 2). Both C4-2B and LNCaP cells were
maintained in RPMI-1640 medium (Invitrogen, Carlsbad,
CA) supplemented with 5% fetal bovine serum (FBS; Inv-
itrogen). Dihydrotestosterone (DHT; Sigma Chemical
Co., St. Louis, MI) was administered in phenol red-free
RPMI-1640 supplemented with 5% charcoal-stripped FBS
(CSS; Gemini, West Sacremento, CA). An N-terminal AR
antibody (N20) was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA).
ChIP
ChIP was carried out essentially as described previously
[22]. C4-2B and LNCaP cells were cultured for 3 days in
phenol red-free RPMI-1640 supplemented with 5% CSS,
then treated for 4-hr with 10 nM DHT, followed by cross-
linking with 1% formaldehyde for 10 minutes. After son-
ication, chromatin was immunoprecipitated overnight at
4°C with either anti-AR antibodies or isotype-matched
IgG. AR occupancy was assessed by PCR with locus-spe-
cific primers (see Additional file 1) using material from
several independent ChIPs. Serial dilutions of genomic
DNA were amplified to ensure that PCR was performed
within a dynamic range.Page 11 of 15
(page number not for citation purposes)
Molecular Cancer 2007, 6:39 http://www.molecular-cancer.com/content/6/1/39ChIP Display (CD)
We have recently described the CD procedure in detail
[19]. Briefly, DNA from AR ChIP and IgG control ChIP
was dephosphorylated using shrimp alkaline phosphatase
(NEB, Ipswich, MA) and digested with AvaII (NEB). The
AvaII fragments were subjected to ligation-mediated PCR
using each of 36 combinations of eight primers. Each
primer had A or T at the +3 position of the AvaII site, and
A,T,G, or C at the so-called +6 position, immediately
internal to the AvaII site [19]. In the present paper, prim-
ers are named by the nucleotides occupying these two
positions. For example, the PCR primer 'AC' is the one
with A at the +3 and C at the +6 position. Each PCR reac-
tion in the present study was performed in duplicate, with
a 1°C difference in the annealing temperature (see Fig.
1A). The amplified material form 2–3 independent AR
ChIPs and 2–3 controls was resolved by polyacrylamide
gel electrophoresis (PAGE), and bands enriched in the AR
ChIPs were excised and reamplified. They were then sub-
jected to secondary digestion with HaeIII, HinfI and MspI
(NEB), and sub-fragments were isolated by agarose gel
electrophoresis and sequenced. The sequences were
mapped to the human genome using the SSAHA program
on ENSEMBL [65].
AR siRNA
C4-2B cells (1.5 × 105 cells/well in 6 well plates) were cul-
tured for two days in phenol red-free RPMI-1640 supple-
mented with 5% CSS. The cells were then transfected
using OligofectAMINE (Invitrogen) with 100 nM of either
AR-specific or non-specific siRNA (see Additional file 1) as
previously described [22]. After two days, cells were
treated for 16 hours with 10 nM DHT or ethanol vehicle
prior to analysis of gene expression.
RT-PCR
Cells were grown in six-well plates and RNA was extracted
using Biorad's total RNA mini kit according to manufac-
turer's protocols (Biorad, Hercules, CA). RNA quality was
assessed spectrophotometrically and by agarose gel elec-
trophoresis. High quality RNA (200–1000 ng) was
reverse-transcribed with random hexamers using the Taq-
man reverse transcription reagents kit (Applied Biosys-
tems, Foster City, CA). cDNAs of interest were amplified
using gene specific-primers (see Additional file 1) and the
iQSYBR Green supermix (Biorad). Amplification was per-
formed in triplicate in a 96-well format and monitored in
real time using the Opticon 2 DNA Engine (Biorad). Neg-
ative controls without RNA, without RT and without
cDNA were always included to rule out contamination.
Expression levels were determined using standard curves
for each gene and corrected for 18S ribosomal RNA levels.
Gene expression analysis in clinical PCa specimens
Expression of genes disclosed by ChIP Display was ana-
lyzed in prostate cancer samples using microarray data
collected as part of our previous studies [24]. Briefly, clin-
ical samples were from 40 primary prostate cancers
obtained during radical prostatectomy and 7 AR-positive
metastatic prostate cancer lesions. Twenty-three of the pri-
mary tumors were from patients receiving no therapy
before surgery and the remaining 17 were from patients
after 3 months of goserelin plus flutamide androgen-abla-
tion therapy. All tissues were obtained during routine clin-
ical management at the Memorial Sloan-Kettering Cancer
Center, New York, NY, under protocols approved by the
Institutional Review Board. RNA was extracted from man-
ually-microdissected tissue consisting of 60–80% prostate
cancer cell nuclei, and analyzed as previously described
[24] using the Affymetrix U95 A-E array set. The results are
displayed as a heat-map generated using 'Heatmap
Builder' (Stanford University), with data routed to 50
equal gates for each probeset (row) using a linear grey
scale gradient from white (lowest value) to black (highest
value). Data for each gene was generated using only those
high-fidelity probesets with a grade A annotation as
defined by Affymetrix.
Statistical analysis
We employed the unpaired t-test using GraphPad Instat
version 3.0 for PC to compare mRNA levels for each gene
between DHT-treated and vehicle-treated cells at each
time point, and between the basal levels in LNCaP versus
C4-2B cells. Unless otherwise stated, differences referred
to in the text were assigned a p value of less than 0.05. The
individual p values assigned to each of the comparisons
are provided in additional files 3 and 4.
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